Literature DB >> 16700699

Streptococcus pneumoniae endophthalmitis: a study of 36 cases with special reference to antibiotic resistance and treatment options.

F Soriano1, E Pérez-Trallero, R Pallarés, M A Meseguer, A Fleites, A Gené, A González, J Liñares, J Esteban, F Baquero, E Valdés, C Muñoz-Almagro.   

Abstract

Patients (n = 36) diagnosed with pneumococcal endophthalmitis from six Spanish hospitals between 1986 and 2004 were studied retrospectively. The diagnosis was based on clinical findings, ophthalmological examination, and isolation of Streptococcus pneumoniae from vitreous and/or aqueous humours of 19 patients (definite diagnosis), and from other ocular specimens of 17 patients (probable diagnosis). The mean (+/- SD) age was 69.3 (+/- 16.5) years (range 1.5-89 years), and 20 (55.5%) patients were male. The origin of endophthalmitis was considered exogenous for 34 (94.5%) patients. The most common predisposing factors were previous ocular surgery (n = 25, 69.4%), ocular trauma (n = 5, 13.9%), and close-to-eye radiotherapy (n = 3, 8.3%). Eleven (30.5%) patients underwent evisceration as the first therapeutic measure (primary evisceration), and evisceration was performed after antibiotic treatment failure (secondary evisceration) for six (16.7%) patients. Primary evisceration was performed more commonly (63.6%) during 1998-2004, while secondary evisceration was only performed during 1986-1997. Eighteen (50%) patients received intra-vitreous antibiotics (mainly vancomycin), and 31 (86.1%) patients were given systemic antibiotic therapy. The most frequent pneumococcal serogroups isolated were 6, 19, 9, 15 and 23. Pulsed-field gel electrophoresis analysis of 23 isolates revealed that four belonged to the international clones Spain(23F)-1, Spain(6B)-2, Spain(9V)-3 and Sweden(15A)-25. Non-susceptibility rates (i.e., intermediately-resistant and resistant) were: co-trimoxazole, 44.8%; penicillin, 33.3%; tetracycline, 31.0%; erythromycin, 21.9%; chloramphenicol, 17.9%; rifampicin, 7.4%; cefotaxime, 5.9%; and levofloxacin, 0%. Although uncommon, pneumococcal endophthalmitis is a medical emergency because of the often aggressive clinical course, poor visual outcome and need for evisceration in a large proportion of patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16700699     DOI: 10.1111/j.1469-0691.2006.01418.x

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  14 in total

1.  Immunization with pneumolysin protects against both retinal and global damage caused by Streptococcus pneumoniae endophthalmitis.

Authors:  Melissa E Sanders; Erin W Norcross; Quincy C Moore; Jonathan Fratkin; Hilary Thompson; Mary E Marquart
Journal:  J Ocul Pharmacol Ther       Date:  2010-10-29       Impact factor: 2.671

Review 2.  Perioperative antibiotics for prevention of acute endophthalmitis after cataract surgery.

Authors:  Emily W Gower; Kristina Lindsley; Samantha E Tulenko; Afshan A Nanji; Ilya Leyngold; Peter J McDonnell
Journal:  Cochrane Database Syst Rev       Date:  2017-02-13

3.  The Streptococcus pneumoniae capsule is required for full virulence in pneumococcal endophthalmitis.

Authors:  Melissa E Sanders; Erin W Norcross; Zachary M Robertson; Quincy C Moore; Jonathan Fratkin; Mary E Marquart
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-02-22       Impact factor: 4.799

Review 4.  Perioperative antibiotics for prevention of acute endophthalmitis after cataract surgery.

Authors:  Emily W Gower; Kristina Lindsley; Afshan A Nanji; Ilya Leyngold; Peter J McDonnell
Journal:  Cochrane Database Syst Rev       Date:  2013-07-15

5.  Differential bacterial gene expression during experimental pneumococcal endophthalmitis.

Authors:  Justin A Thornton; Nathan A Tullos; Melissa E Sanders; Granger Ridout; Yong-Dong Wang; Sidney D Taylor; Larry S McDaniel; Mary E Marquart
Journal:  Ophthalmic Res       Date:  2015-03-12       Impact factor: 2.892

6.  Endophthalmitis: Pathogenesis, clinical presentation, management, and perspectives.

Authors:  M Kernt; A Kampik
Journal:  Clin Ophthalmol       Date:  2010-03-24

7.  Cholesterol as treatment for pneumococcal keratitis: cholesterol-specific inhibition of pneumolysin in the cornea.

Authors:  Mary E Marquart; Kathryn S Monds; Clare C McCormick; Sherrina N Dixon; Melissa E Sanders; Julian M Reed; Larry S McDaniel; Armando R Caballero; Richard J O'Callaghan
Journal:  Invest Ophthalmol Vis Sci       Date:  2007-06       Impact factor: 4.799

8.  A comparison of pneumolysin activity and concentration in vitro and in vivo in a rabbit endophthalmitis model.

Authors:  Melissa E Sanders; Erin W Norcross; Quincy C Moore; Chinwendu Onwubiko; Lauren B King; Jonathan Fratkin; Mary E Marquart
Journal:  Clin Ophthalmol       Date:  2008-12

9.  Passive immunization with Pneumovax® 23 and pneumolysin in combination with vancomycin for pneumococcal endophthalmitis.

Authors:  Melissa E Sanders; Sidney Taylor; Nathan Tullos; Erin W Norcross; Quincy C Moore; Hilary Thompson; Lauren B King; Mary E Marquart
Journal:  BMC Ophthalmol       Date:  2013-03-11       Impact factor: 2.209

10.  The cholesterol-dependent cytolysin pneumolysin from Streptococcus pneumoniae binds to lipid raft microdomains in human corneal epithelial cells.

Authors:  Sidney D Taylor; Melissa E Sanders; Nathan A Tullos; Stephen J Stray; Erin W Norcross; Larry S McDaniel; Mary E Marquart
Journal:  PLoS One       Date:  2013-04-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.